Cargando…
Hybrid membrane-coated nanosuspensions for multi-modal anti-glioma therapy via drug and antigen delivery
BACKGROUND: Glioma is one of the deadliest human cancers. Although many therapeutic strategies for glioma have been explored, these strategies are seldom used in the clinic. The challenges facing the treatment of glioma not only involve the development of chemotherapeutic drugs and immunotherapeutic...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606100/ https://www.ncbi.nlm.nih.gov/pubmed/34801032 http://dx.doi.org/10.1186/s12951-021-01110-0 |
_version_ | 1784602282529128448 |
---|---|
author | Hao, Wenyan Cui, Yuexin Fan, Yueyue Chen, Mengyu Yang, Guobao Wang, Yuli Yang, Meiyan Li, Zhiping Gong, Wei Yang, Yang Gao, Chunsheng |
author_facet | Hao, Wenyan Cui, Yuexin Fan, Yueyue Chen, Mengyu Yang, Guobao Wang, Yuli Yang, Meiyan Li, Zhiping Gong, Wei Yang, Yang Gao, Chunsheng |
author_sort | Hao, Wenyan |
collection | PubMed |
description | BACKGROUND: Glioma is one of the deadliest human cancers. Although many therapeutic strategies for glioma have been explored, these strategies are seldom used in the clinic. The challenges facing the treatment of glioma not only involve the development of chemotherapeutic drugs and immunotherapeutic agents, but also the lack of a powerful platform that could deliver these two moieties to the targeted sites. Herein, we developed chemoimmunotherapy delivery vehicles based on C6 cell membranes and DC membranes to create hybrid membrane-coated DTX nanosuspensions (DNS-[C6&DC]m). RESULTS: Results demonstrated successful hybrid membrane fusion and nanosuspension functionalization, and DNS-[C6&DC]m could be used for different modes of anti-glioma therapy. For drug delivery, membrane coating could be applied to target the source cancer cells via a homotypic-targeting mechanism of the C6 cell membrane. For cancer immunotherapy, biomimetic nanosuspension enabled an immune response based on the professional antigen-presenting characteristic of the dendritic cell membrane (DCm), which carry the full array of cancer cell membrane antigens and facilitate the uptake of membrane-bound tumor antigens for efficient presentation and downstream immune n. CONCLUSION: DNS-[C6&DC]m is a multifunctional biomimetic nano-drug delivery system with the potential to treat gliomas through tumor-targeted drug delivery combined with immunotherapy, thereby presenting a promising approach that may be utilized for multiple modes of cancer therapy. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-021-01110-0. |
format | Online Article Text |
id | pubmed-8606100 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-86061002021-11-22 Hybrid membrane-coated nanosuspensions for multi-modal anti-glioma therapy via drug and antigen delivery Hao, Wenyan Cui, Yuexin Fan, Yueyue Chen, Mengyu Yang, Guobao Wang, Yuli Yang, Meiyan Li, Zhiping Gong, Wei Yang, Yang Gao, Chunsheng J Nanobiotechnology Research BACKGROUND: Glioma is one of the deadliest human cancers. Although many therapeutic strategies for glioma have been explored, these strategies are seldom used in the clinic. The challenges facing the treatment of glioma not only involve the development of chemotherapeutic drugs and immunotherapeutic agents, but also the lack of a powerful platform that could deliver these two moieties to the targeted sites. Herein, we developed chemoimmunotherapy delivery vehicles based on C6 cell membranes and DC membranes to create hybrid membrane-coated DTX nanosuspensions (DNS-[C6&DC]m). RESULTS: Results demonstrated successful hybrid membrane fusion and nanosuspension functionalization, and DNS-[C6&DC]m could be used for different modes of anti-glioma therapy. For drug delivery, membrane coating could be applied to target the source cancer cells via a homotypic-targeting mechanism of the C6 cell membrane. For cancer immunotherapy, biomimetic nanosuspension enabled an immune response based on the professional antigen-presenting characteristic of the dendritic cell membrane (DCm), which carry the full array of cancer cell membrane antigens and facilitate the uptake of membrane-bound tumor antigens for efficient presentation and downstream immune n. CONCLUSION: DNS-[C6&DC]m is a multifunctional biomimetic nano-drug delivery system with the potential to treat gliomas through tumor-targeted drug delivery combined with immunotherapy, thereby presenting a promising approach that may be utilized for multiple modes of cancer therapy. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-021-01110-0. BioMed Central 2021-11-20 /pmc/articles/PMC8606100/ /pubmed/34801032 http://dx.doi.org/10.1186/s12951-021-01110-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Hao, Wenyan Cui, Yuexin Fan, Yueyue Chen, Mengyu Yang, Guobao Wang, Yuli Yang, Meiyan Li, Zhiping Gong, Wei Yang, Yang Gao, Chunsheng Hybrid membrane-coated nanosuspensions for multi-modal anti-glioma therapy via drug and antigen delivery |
title | Hybrid membrane-coated nanosuspensions for multi-modal anti-glioma therapy via drug and antigen delivery |
title_full | Hybrid membrane-coated nanosuspensions for multi-modal anti-glioma therapy via drug and antigen delivery |
title_fullStr | Hybrid membrane-coated nanosuspensions for multi-modal anti-glioma therapy via drug and antigen delivery |
title_full_unstemmed | Hybrid membrane-coated nanosuspensions for multi-modal anti-glioma therapy via drug and antigen delivery |
title_short | Hybrid membrane-coated nanosuspensions for multi-modal anti-glioma therapy via drug and antigen delivery |
title_sort | hybrid membrane-coated nanosuspensions for multi-modal anti-glioma therapy via drug and antigen delivery |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606100/ https://www.ncbi.nlm.nih.gov/pubmed/34801032 http://dx.doi.org/10.1186/s12951-021-01110-0 |
work_keys_str_mv | AT haowenyan hybridmembranecoatednanosuspensionsformultimodalantigliomatherapyviadrugandantigendelivery AT cuiyuexin hybridmembranecoatednanosuspensionsformultimodalantigliomatherapyviadrugandantigendelivery AT fanyueyue hybridmembranecoatednanosuspensionsformultimodalantigliomatherapyviadrugandantigendelivery AT chenmengyu hybridmembranecoatednanosuspensionsformultimodalantigliomatherapyviadrugandantigendelivery AT yangguobao hybridmembranecoatednanosuspensionsformultimodalantigliomatherapyviadrugandantigendelivery AT wangyuli hybridmembranecoatednanosuspensionsformultimodalantigliomatherapyviadrugandantigendelivery AT yangmeiyan hybridmembranecoatednanosuspensionsformultimodalantigliomatherapyviadrugandantigendelivery AT lizhiping hybridmembranecoatednanosuspensionsformultimodalantigliomatherapyviadrugandantigendelivery AT gongwei hybridmembranecoatednanosuspensionsformultimodalantigliomatherapyviadrugandantigendelivery AT yangyang hybridmembranecoatednanosuspensionsformultimodalantigliomatherapyviadrugandantigendelivery AT gaochunsheng hybridmembranecoatednanosuspensionsformultimodalantigliomatherapyviadrugandantigendelivery |